Merck & Co. scored a hepatitis C patent win against Gilead Sciences on Tuesday. And if the jury verdict stands, Merck could collect big royalties on Gilead's megablockbuster hep C drugs Sovaldi and Harvoni.
Marketing a drug with a black-box warning is always challenging, but even more difficult when the treatment category is already flooded with less risky and inexpensive OTC options.
Are you the type of consumer motivated by fear? Or are you more likely to take action based on advice from a humorous celeb? Doesn't matter--Merck & Co., in a push to boost vaccine sales before new competition arrives, has a shingles commercial for you.
Last fall, the folks behind Harvard's Blavatnik Biomedical Accelerator took a promising preclinical program from the lab of Matthew Shair and essentially posted a "for sale" sign on it--touting its potential for mounting a fresh line of attack on acute myeloid leukemia with a counterintuitive therapeutic strategy ready for the clinic. The move didn't escape Merck's attention.
Three years ago, doctors in Europe displayed grave doubts about using biosimilars instead of branded biologics on their patients. But after a couple of years of experience with a biosimilar of Merck's Remicade (infliximab) from Hospira and Celltrion, a new report finds doctors are much more responsive to the biologic copies.
Hep C drugmakers are struggling against restrictive coverage decisions that often limit treatment to the sickest patients. But now, companies are enjoying a bright point after the Veterans Affairs Department said that it's expanding hep C treatment to all veterans.
Citing "seriously flawed" methodology and "unjustified" claims, the journal Vaccine has permanently withdrawn a previously published study critical of Merck's Gardasil.
The man who helped lead Merck & Co. out of difficulties with a slew of vaccine manufacturing issues is taking the top manufacturing job at the Big Pharma company.
Sanofi Pasteur MSD, the European vaccines joint venture between pharma giants Sanofi and Merck, has been around for 22 years. But now, the pair has decided that's long enough.
Merck & Co. isn't just battling Gilead Sciences for market share with its brand-new hepatitis C drug. It's also fighting in court for a multibillion-dollar piece of Gilead's blockbuster franchise.